| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-88558-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF4030-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-78264SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-92792-0.02ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-00002-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-78264SS | |||
| BSA Free | NBP1-78264 | |||
![Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP1-88558] - Staining in human placenta and pancreas tissues using anti-BNIP3L antibody. Corresponding BNIP3L RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunohistochemistry-Paraffin-NBP1-88558-img0009.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP1-88558] - Staining in human placenta and pancreas tissues using anti-BNIP3L antibody. Corresponding BNIP3L RNA-seq data are presented for the same tissues.")
![<b>Orthogonal Strategies Validation. </b>Western Blot: BNIP3L Antibody [NBP1-88558] - UCB-hMSCs were exposed to normoxia or hypoxia. (D) The mRNA expressions of PINK1, BNIP3, NIX and FUNDC1 were analyzed by quantitative real-time PCR (qPCR). n = 5. (E) The protein expressions of PINK1, BNIP3, NIX and B-actin were assessed by western blot. n = 4. *p < 0.05 versus control. Image collected and cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S2213231717303804) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Western-Blot-NBP1-88558-img0010.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: BNIP3L Antibody [NBP1-88558] - Vehicle or RU 486 (5 mg/kg) injected mice were presented with/without corticosterone (10 mg/kg) for 3 days. The expressions of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1 alpha NBP1-04676) and NIX (BNIP3L NBP1-88558) were visualized via western blotting. Loading control is beta-actin. n = 5. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33473105/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BNIP3L Antibody-Western Blot-NBP1-88558-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: BNIP3L Antibody [NBP1-88558] - Staining of human cell line U-2 OS shows localization to nuclear speckles & mitochondria. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88558-img0006.jpg)
![Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP1-88558] - Staining of human pancreas shows low expression as expected.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunohistochemistry-Paraffin-NBP1-88558-img0007.jpg)
![Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP1-88558] - Staining of human placenta shows high expression.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunohistochemistry-Paraffin-NBP1-88558-img0008.jpg)
![Western Blot: BNIP3L Antibody [NBP1-88558] - Role of PGC1 alpha in NIX-dependent mitophagy.a–e Nontargeting (NT) or GR siRNA was transfected to hippocampal neurons & SH-SY5Y cells for 24 h prior to corticosterone & cortisol for 12 h, respectively. a, b Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1 alpha ) expression was detected in western blot where beta -actin was used as a loading control in both cell types. n = 5. c Colocalization of PGC1 alpha (red) & DAPI (blue) in hippocampal neurons was visualized with SRRF imaging system. Scale bars, 20 μm (magnification, ×1000). n = 5. d Colocalization of PGC1 alpha (green) & DAPI (blue) in SH-SY5Y was visualized with SRRF imaging system. Scale bars, 20 μm (magnification, ×1000). n = 5. e PGC1 alpha protein expressions in subcellular fraction samples were detected by western blotting. Lamin A/C & alpha -tubulin were used as a nuclear & cytosolic loading control, respectively. n = 5. f, g SH-SY5Y cells were transfected with pcDNA3.1/c-eGFP or pcDNA3.1/PPARGC1A-c-eGFP vector for 24 h prior to cortisol treatment for 24 h. f NIX expression was detected in western blot where beta -actin was used as a loading control. n = 5. g TOMM20 levels were detected by western blot. Loading control for western blot is beta -actin. n = 5. All blots & immunofluorescence images are representative. n = 5 from independent experiments with two technical replicates each. Quantitative data are presented as a mean ± S.E.M. Two-sided two-way ANOVA was conducted. ** indicates p < 0.01 versus control. #, ## indicates p < 0.05, p < 0.01 versus corticosterone in hippocampal neurons & cortisol in SH-SY5Y, respectively. Data are provided as a Source data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33473105), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-310202416121937.jpg)
![Western Blot: BNIP3L Antibody [NBP1-88558] - GR-dependent downregulation of NIX expression via PGC1 alpha .a, b Nontargeting (NT) or GR siRNA was transfected to hippocampal neurons & SH-SY5Y cells for 24 h prior to corticosterone & cortisol for 24 h, respectively. NIX expression was detected in western blot where beta -actin was used as a loading control. n = 5. c SH-SY5Y cells were incubated with cortisol for 6 h. The mRNA expression levels of genes associated with nuclear receptors & coregulators were assessed by RT2 Profiler PCR array. Heat maps with hierarchical clustering were acquired by using the GeneGlobe Data analysis Center on Qiagen website. n = 3. d A thousand base pair upstream of the first codon of the PPARGC1A was described & the putative GRE binding sequence was emphasized with yellow labeling. e SH-SY5Y cells were incubated with cortisol for 6 h. DNA was immunoprecipitated with IgG, RNA polymerase (RNAPol), & glucocorticoid receptor (GR) antibody. The immunoprecipitation & input samples were amplified with primers of GAPDH & PPARGC1A gene. n = 5. All blots are representative. n = 3 or 5 from independent experiments with two technical replicates each, respectively. Quantitative data are presented as a mean ± S.E.M. Two-sided two-way ANOVA was conducted in Fig. 6a, b. Two-sided unpaired student’s t test was conducted in Fig. 6e. ** indicates p < 0.01 versus control. ## indicates p < 0.01 versus corticosterone in hippocampal neurons & cortisol in SH-SY5Y, respectively. Data are provided as a Source data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33473105), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-310202416121914.jpg)
![Western Blot: BNIP3L Antibody [NBP1-88558] - GR-dependent downregulation of NIX expression via PGC1 alpha .a, b Nontargeting (NT) or GR siRNA was transfected to hippocampal neurons & SH-SY5Y cells for 24 h prior to corticosterone & cortisol for 24 h, respectively. NIX expression was detected in western blot where beta -actin was used as a loading control. n = 5. c SH-SY5Y cells were incubated with cortisol for 6 h. The mRNA expression levels of genes associated with nuclear receptors & coregulators were assessed by RT2 Profiler PCR array. Heat maps with hierarchical clustering were acquired by using the GeneGlobe Data analysis Center on Qiagen website. n = 3. d A thousand base pair upstream of the first codon of the PPARGC1A was described & the putative GRE binding sequence was emphasized with yellow labeling. e SH-SY5Y cells were incubated with cortisol for 6 h. DNA was immunoprecipitated with IgG, RNA polymerase (RNAPol), & glucocorticoid receptor (GR) antibody. The immunoprecipitation & input samples were amplified with primers of GAPDH & PPARGC1A gene. n = 5. All blots are representative. n = 3 or 5 from independent experiments with two technical replicates each, respectively. Quantitative data are presented as a mean ± S.E.M. Two-sided two-way ANOVA was conducted in Fig. 6a, b. Two-sided unpaired student’s t test was conducted in Fig. 6e. ** indicates p < 0.01 versus control. ## indicates p < 0.01 versus corticosterone in hippocampal neurons & cortisol in SH-SY5Y, respectively. Data are provided as a Source data file. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33473105), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-310202416121960.jpg)
![Western Blot: BNIP3L Antibody [NBP1-88558] - Effects of hypoxia on mitophagy regulator expressions & mitophagy in UCB-hMSCs. (A) UCB-hMSCs incubated w/ various times of hypoxia (0–48 h). Cells stained w/ Mitotracker™. n = 6 (magnification, ×1,200). Scale bars, 50 µm. (B) The expressions of COX4 & beta -actin detected by western blot. n = 4. (C) UCB-hMSCs exposed to 24 h of normoxia or hypoxia. Cells immuno-stained w/ COX4 & LC3B-specific antibodies (magnification, ×600). Scale bars, 37.5 µm. (D) The mRNA expressions of PINK1, BNIP3, NIX & FUNDC1 analyzed by quantitative real-time PCR (qPCR). n = 5. (E) The protein expressions of PINK1, BNIP3, NIX & beta -actin assessed by western blot. n = 4. (F, G) siRNAs of PINK1, BNIP3, NIX or non-targeting (NT) transfected to UCB-hMSCs prior to hypoxia treatment for 24 h. COX4 & beta -actin expressions assessed by western blot. n = 4 (F). Cells immunostained w/ COX4 & PI. n = 3 (magnification, ×400). All scale bars, 50 µm. COX4 fluorescence intensity analyzed by luminometer. n = 5 (G). (H) BNIP3 siRNA transfected to UCB-hMSCs prior to hypoxia treatment for 24 h. Cells stained w/ Mitotracker™. n = 6 (magnification, ×1,200). Scale bars, 50 µm. (I) BNIP3, beta -tubulin & COX4 w/ cytosol & mitochondrial fractionized samples detected by western blot. (J) Cells incubated w/ hypoxia or normoxia for 24 h. Cells immuno-stained w/ BNIP3 & LC3B-specific antibodies. (magnification, ×600). Scale bars, 37.5 µm. Western blot data normalized by beta -actin, & qPCR data normalized by ACTB mRNA expression level. Quantitative data are presented as a mean ± S.E.M. All blot & confocal images are representative. *p < 0.05 versus control, #p < 0.05 versus hypoxia. Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S2213231717303804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-310202416121983.jpg)
![Immunocytochemistry/ Immunofluorescence: BNIP3L Antibody [NBP1-88558] - The role of PA in BNIP3 silenced UCB-hMSC survival in the mouse skin wound healing model. (A) Mouse skin wound surgery with UCB-hMSC transplantation was performed as described in Section 2. Representative gross wound images were acquired at post injection days 0, 4, 8, 12. Skin wound sizes at day 8 were compared with wound size at day 0. n = 5. (B) Tissue slide samples were stained with hematoxylin & eosin. Low & high magnified histological gross images are shown in the left & right panels, respectively. Scale bars, 260 µm (magnification, ×40) & 100 µm (magnification, ×100). n = 5. (C) Representative images of blood vessels in skin wounds on day 12 (top panel). Vessel density was analyzed by using ImageJ program (bottom panel). n = 5. (D-F) Histological tissue samples were immuno-stained with CD31, alpha -SMA, & HNA-specific antibodies & PI for counterstaining. alpha -SMA & HNA-positive cells were visualized by confocal microscopy. The number of CD31 & alpha -SMA-positive cells in high power field (HPF), & the percentage of HNA-positive cells in total cells were analyzed by using Metamorph software. Scale bars, 100 µm (magnification, ×100). n = 5. Data are presented as a mean ± S.E.M. $p < 0.05 versus vehicle group, *p < 0.05 versus UCB-hMSC group given NT siRNA, #p < 0.05 versus UCB-hMSC group given NT siRNA with hypoxia pretreatment, @p < 0.05 versus UCB-hMSC group given BNIP3 siRNA with hypoxia pretreatment. Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S2213231717303804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-310202416113531.jpg)
![Immunocytochemistry/ Immunofluorescence: BNIP3L Antibody [NBP1-88558] - The role of PA in BNIP3 silenced UCB-hMSC survival in the mouse skin wound healing model. (A) Mouse skin wound surgery with UCB-hMSC transplantation was performed as described in Section 2. Representative gross wound images were acquired at post injection days 0, 4, 8, 12. Skin wound sizes at day 8 were compared with wound size at day 0. n = 5. (B) Tissue slide samples were stained with hematoxylin & eosin. Low & high magnified histological gross images are shown in the left & right panels, respectively. Scale bars, 260 µm (magnification, ×40) & 100 µm (magnification, ×100). n = 5. (C) Representative images of blood vessels in skin wounds on day 12 (top panel). Vessel density was analyzed by using ImageJ program (bottom panel). n = 5. (D-F) Histological tissue samples were immuno-stained with CD31, alpha -SMA, & HNA-specific antibodies & PI for counterstaining. alpha -SMA & HNA-positive cells were visualized by confocal microscopy. The number of CD31 & alpha -SMA-positive cells in high power field (HPF), & the percentage of HNA-positive cells in total cells were analyzed by using Metamorph software. Scale bars, 100 µm (magnification, ×100). n = 5. Data are presented as a mean ± S.E.M. $p < 0.05 versus vehicle group, *p < 0.05 versus UCB-hMSC group given NT siRNA, #p < 0.05 versus UCB-hMSC group given NT siRNA with hypoxia pretreatment, @p < 0.05 versus UCB-hMSC group given BNIP3 siRNA with hypoxia pretreatment. Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S2213231717303804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-310202416114791.jpg)
![Immunocytochemistry/ Immunofluorescence: BNIP3L Antibody [NBP1-88558] - The role of PA in BNIP3 silenced UCB-hMSC survival in the mouse skin wound healing model. (A) Mouse skin wound surgery with UCB-hMSC transplantation was performed as described in Section 2. Representative gross wound images were acquired at post injection days 0, 4, 8, 12. Skin wound sizes at day 8 were compared with wound size at day 0. n = 5. (B) Tissue slide samples were stained with hematoxylin & eosin. Low & high magnified histological gross images are shown in the left & right panels, respectively. Scale bars, 260 µm (magnification, ×40) & 100 µm (magnification, ×100). n = 5. (C) Representative images of blood vessels in skin wounds on day 12 (top panel). Vessel density was analyzed by using ImageJ program (bottom panel). n = 5. (D-F) Histological tissue samples were immuno-stained with CD31, alpha -SMA, & HNA-specific antibodies & PI for counterstaining. alpha -SMA & HNA-positive cells were visualized by confocal microscopy. The number of CD31 & alpha -SMA-positive cells in high power field (HPF), & the percentage of HNA-positive cells in total cells were analyzed by using Metamorph software. Scale bars, 100 µm (magnification, ×100). n = 5. Data are presented as a mean ± S.E.M. $p < 0.05 versus vehicle group, *p < 0.05 versus UCB-hMSC group given NT siRNA, #p < 0.05 versus UCB-hMSC group given NT siRNA with hypoxia pretreatment, @p < 0.05 versus UCB-hMSC group given BNIP3 siRNA with hypoxia pretreatment. Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S2213231717303804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-310202416114754.jpg)
![Immunocytochemistry/ Immunofluorescence: BNIP3L Antibody [NBP1-88558] - The role of PA in BNIP3 silenced UCB-hMSC survival in the mouse skin wound healing model. (A) Mouse skin wound surgery with UCB-hMSC transplantation was performed as described in Section 2. Representative gross wound images were acquired at post injection days 0, 4, 8, 12. Skin wound sizes at day 8 were compared with wound size at day 0. n = 5. (B) Tissue slide samples were stained with hematoxylin & eosin. Low & high magnified histological gross images are shown in the left & right panels, respectively. Scale bars, 260 µm (magnification, ×40) & 100 µm (magnification, ×100). n = 5. (C) Representative images of blood vessels in skin wounds on day 12 (top panel). Vessel density was analyzed by using ImageJ program (bottom panel). n = 5. (D-F) Histological tissue samples were immuno-stained with CD31, alpha -SMA, & HNA-specific antibodies & PI for counterstaining. alpha -SMA & HNA-positive cells were visualized by confocal microscopy. The number of CD31 & alpha -SMA-positive cells in high power field (HPF), & the percentage of HNA-positive cells in total cells were analyzed by using Metamorph software. Scale bars, 100 µm (magnification, ×100). n = 5. Data are presented as a mean ± S.E.M. $p < 0.05 versus vehicle group, *p < 0.05 versus UCB-hMSC group given NT siRNA, #p < 0.05 versus UCB-hMSC group given NT siRNA with hypoxia pretreatment, @p < 0.05 versus UCB-hMSC group given BNIP3 siRNA with hypoxia pretreatment. Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S2213231717303804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-310202416121953.jpg)
![Immunocytochemistry/ Immunofluorescence: BNIP3L Antibody [NBP1-88558] - The role of PA in BNIP3 silenced UCB-hMSC survival in the mouse skin wound healing model. (A) Mouse skin wound surgery with UCB-hMSC transplantation was performed as described in Section 2. Representative gross wound images were acquired at post injection days 0, 4, 8, 12. Skin wound sizes at day 8 were compared with wound size at day 0. n = 5. (B) Tissue slide samples were stained with hematoxylin & eosin. Low & high magnified histological gross images are shown in the left & right panels, respectively. Scale bars, 260 µm (magnification, ×40) & 100 µm (magnification, ×100). n = 5. (C) Representative images of blood vessels in skin wounds on day 12 (top panel). Vessel density was analyzed by using ImageJ program (bottom panel). n = 5. (D-F) Histological tissue samples were immuno-stained with CD31, alpha -SMA, & HNA-specific antibodies & PI for counterstaining. alpha -SMA & HNA-positive cells were visualized by confocal microscopy. The number of CD31 & alpha -SMA-positive cells in high power field (HPF), & the percentage of HNA-positive cells in total cells were analyzed by using Metamorph software. Scale bars, 100 µm (magnification, ×100). n = 5. Data are presented as a mean ± S.E.M. $p < 0.05 versus vehicle group, *p < 0.05 versus UCB-hMSC group given NT siRNA, #p < 0.05 versus UCB-hMSC group given NT siRNA with hypoxia pretreatment, @p < 0.05 versus UCB-hMSC group given BNIP3 siRNA with hypoxia pretreatment. Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S2213231717303804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88558_rabbit-polyclonal-bnip3l-antibody-31020241613647.jpg)
![Immunocytochemistry/Immunofluorescence: BNIP3L Antibody (HL1203) - Azide and BSA Free [NBP3-25384] - BNIP3L antibody [HL1203] detects BNIP3L protein at mitochondria by immunofluorescent analysis. Sample: Mock and treated HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: BNIP3L stained by BNIP3L antibody [HL1203] (NBP3-25384) diluted at 1:500. Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp3-25384_rabbit-bnip3l-mab-hl1203-azide-and-bsa-free-2120249432824.jpg "Immunocytochemistry/Immunofluorescence: BNIP3L Antibody (HL1203) - Azide and BSA Free [NBP3-25384] - BNIP3L antibody [HL1203] detects BNIP3L protein at mitochondria by immunofluorescent analysis. Sample: Mock and treated HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: BNIP3L stained by BNIP3L antibody [HL1203] (NBP3-25384) diluted at 1:500. Blue: Fluoroshield with DAPI .")
![Western Blot: BNIP3L Antibody (HL1203) - Azide and BSA Free [NBP3-25384] - Whole cell extract (30 ug) was separated by 12% SDS-PAGE, and the membrane was blotted with BNIP3L antibody [HL1203] (NBP3-25384) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp3-25384_rabbit-bnip3l-mab-hl1203-azide-and-bsa-free-2120249415956.jpg)
![Immunohistochemistry-Paraffin: BNIP3L Antibody (HL1203) - Azide and BSA Free [NBP3-25384] - BNIP3L antibody [HL1203] detects BNIP3L protein by immunohistochemical analysis. Sample: Paraffin-embedded mouse tissues. BNIP3L stained by BNIP3L antibody [HL1203] (NBP3-25384) diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp3-25384_rabbit-bnip3l-mab-hl1203-azide-and-bsa-free-2120249413336.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: BNIP3L Antibody (HL1203) - Azide and BSA Free [NBP3-25384] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with BNIP3L antibody [HL1203] (NBP3-25384) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp3-25384_rabbit-bnip3l-mab-hl1203-azide-and-bsa-free-212024940822.jpg)
![Immunohistochemistry-Paraffin: BNIP3L Antibody (HL1203) - Azide and BSA Free [NBP3-25384] - BNIP3L antibody [HL1203] detects BNIP3L protein by immunohistochemical analysis. Sample: Paraffin-embedded rat tissues. BNIP3L stained by BNIP3L antibody [HL1203] (NBP3-25384) diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp3-25384_rabbit-bnip3l-mab-hl1203-azide-and-bsa-free-2120249432899.jpg)
![Immunohistochemistry-Paraffin: BNIP3L Antibody (HL1203) - Azide and BSA Free [NBP3-25384] - BNIP3L antibody [HL1203] detects BNIP3L protein at mitochondria by immunohistochemical analysis. Sample: Paraffin-embedded mouse kidney. BNIP3L stained by BNIP3L antibody [HL1203] (NBP3-25384) diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp3-25384_rabbit-bnip3l-mab-hl1203-azide-and-bsa-free-2120249355569.jpg)
![Immunocytochemistry/Immunofluorescence: BNIP3L Antibody (HL1203) - Azide and BSA Free [NBP3-25384] - BNIP3L antibody [HL1203] detects BNIP3L protein at mitochondria by immunofluorescent analysis. Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: BNIP3L stained by BNIP3L antibody [HL1203] (NBP3-25384) diluted at 1:500. Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp3-25384_rabbit-bnip3l-mab-hl1203-azide-and-bsa-free-2120249374974.jpg)
![Immunocytochemistry/Immunofluorescence: BNIP3L Antibody [NBP1-78264] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-BNIP3L (NBP1-78264) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with and anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-78264-img0005.jpg "Immunocytochemistry/Immunofluorescence: BNIP3L Antibody [NBP1-78264] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-BNIP3L (NBP1-78264) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with and anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry: BNIP3L Antibody [NBP1-78264] - Analysis of BNIP3L in mouse prostate using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunohistochemistry-NBP1-78264-img0004.jpg)
![Western Blot: BNIP3L Antibody (JE59-98) [NBP3-32087] - Western blot analysis of BNIP3L on different lysates with Rabbit anti-BNIP3L antibody (NBP3-32087) at 1/2,000 dilution. Lane 1: 293T cell lysate Lane 2: HeLa cell lysate Lane 3: MCF7 cell lysate Lane 4: COS-1 cell lysate Lysates/proteins at 20 ug/Lane. Predicted band size: 24 kDa Observed band size: 37 kDa Exposure time: 1 minute 21 seconds; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (NBP3-32087) at 1/2,000 dilution was used in 5% NFDM/TBST at 4C overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1/50,000 dilution was used for 1 hour at room temperature.](http://images.novusbio.com/fullsize/nbp3-32087_rabbit-bnip3l-mab-je59-98-27820241631666.jpg "Western Blot: BNIP3L Antibody (JE59-98) [NBP3-32087] - Western blot analysis of BNIP3L on different lysates with Rabbit anti-BNIP3L antibody (NBP3-32087) at 1/2,000 dilution. Lane 1: 293T cell lysate Lane 2: HeLa cell lysate Lane 3: MCF7 cell lysate Lane 4: COS-1 cell lysate Lysates/proteins at 20 ug/Lane. Predicted band size: 24 kDa Observed band size: 37 kDa Exposure time: 1 minute 21 seconds; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (NBP3-32087) at 1/2,000 dilution was used in 5% NFDM/TBST at 4C overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1/50,000 dilution was used for 1 hour at room temperature.")
![Immunohistochemistry: BNIP3L Antibody (JE59-98) [NBP3-32087] - Immunohistochemical analysis of paraffin-embedded human bone marrow tissue with Rabbit anti-BNIP3L antibody (NBP3-32087) at 1/500 dilution. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (NBP3-32087) at 1/500 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.](http://images.novusbio.com/fullsize/nbp3-32087_rabbit-bnip3l-mab-je59-98-2982024143525.jpg)
![Immunocytochemistry/ Immunofluorescence: BNIP3L Antibody (JE59-98) [NBP3-32087] - Immunocytochemistry analysis of HeLa cells labeling BNIP3L with Rabbit anti-BNIP3L antibody (NBP3-32087) at 1/200 dilution. Cells were fixed in 4% paraformaldehyde for 20 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 5 minutes at room temperature, then blocked with 1% BSA in 10% negative goat serum for 1 hour at room temperature. Cells were then incubated with Rabbit anti-BNIP3L antibody (NBP3-32087) at 1/200 dilution in 1% BSA in PBST overnight at 4 ℃. Goat Anti-Rabbit IgG H&L (iFluor™ 488) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. Nuclear DNA was labelled in blue with DAPI. Beta tubulin (red) was stained at 1/100 dilution overnight at +4℃. Goat Anti-Mouse IgG H&L (iFluor™ 594) was used as the secondary antibody at 1/1,000 dilution.](http://images.novusbio.com/fullsize/nbp3-32087_rabbit-bnip3l-mab-je59-98-292024119232.jpg)
![Flow Cytometry: BNIP3L Antibody (JE59-98) [NBP3-32087] - Flow cytometric analysis of HeLa cells labeling BNIP3L. Cells were fixed and permeabilized. Then stained with the primary antibody (NBP3-32087, 1μg/mL) (red) compared with Rabbit IgG Isotype Control (green). After incubation of the primary antibody at +4℃ for an hour, the cells were stained with a iFluor™ 488 conjugate-Goat anti-Rabbit IgG Secondary antibody at 1/1,000 dilution for 30 minutes at +4℃. Unlabelled sample was used as a control (cells without incubation with primary antibody; black).](http://images.novusbio.com/fullsize/nbp3-32087_rabbit-bnip3l-mab-je59-98-29202416453213.jpg)
![Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP2-92792] - Immunohistochemistry of paraffin-embedded rat kidney using BNIP3L Rabbit pAb (NBP2-92792) at dilution of 1:100 (40x lens). Perform high pressure antigen retrieval with 10 mM citrate buffer pH 6.0 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunohistochemistry-Paraffin-NBP2-92792-img0003.jpg "Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP2-92792] - Immunohistochemistry of paraffin-embedded rat kidney using BNIP3L Rabbit pAb (NBP2-92792) at dilution of 1:100 (40x lens). Perform high pressure antigen retrieval with 10 mM citrate buffer pH 6.0 before commencing with IHC staining protocol.")
![Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP2-92792] - Immunohistochemistry of paraffin-embedded mouse lung using BNIP3L Rabbit pAb (NBP2-92792) at dilution of 1:100 (40x lens). Perform high pressure antigen retrieval with 10 mM citrate buffer pH 6.0 before commencing with IHC staining protocol.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunohistochemistry-Paraffin-NBP2-92792-img0002.jpg)
![Immunocytochemistry/ Immunofluorescence: BNIP3L Antibody - Azide and BSA Free [NBP2-92792] - Immunofluorescence analysis of NIH/3T3 cells using BNIP3L Rabbit pAb at dilution of 1:100 (40x lens). Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.](http://images.novusbio.com/fullsize/nbp2-92792_rabbit-polyclonal-bnip3l-antibody-42202514275234.jpg)
![Western Blot: BNIP3L Antibody - Azide and BSA Free [NBP2-92792] - Western blot analysis of lysates from PC-12 cells using BNIP3L Rabbit pAb at 1:1000 dilution incubated overnight at 4C.Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25 ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Enhanced Kit.Exposure time: 60s.](http://images.novusbio.com/fullsize/nbp2-92792_rabbit-polyclonal-bnip3l-antibody-42202514264491.jpg)
![Western Blot: BNIP3L Antibody [NBP3-00002] - Anti-BNIP3L rabbit polyclonal antibody at 1:200 dilution. Lane A: K562 Whole Cell Lysate Lysates/proteins at 30 ug per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 24 kDa. Observed band size: 37 kDa](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Western-Blot-NBP3-00002-img0006.jpg "Western Blot: BNIP3L Antibody [NBP3-00002] - Anti-BNIP3L rabbit polyclonal antibody at 1:200 dilution. Lane A: K562 Whole Cell Lysate Lysates/proteins at 30 ug per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 24 kDa. Observed band size: 37 kDa")
![Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP3-00002] - Immunochemical staining of human BNIP3L in human kidney with rabbit polyclonal antibody at 1:1000 dilution, formalin-fixed paraffin embedded sections.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunohistochemistry-Paraffin-NBP3-00002-img0004.jpg)
![Immunohistochemistry-Paraffin: BNIP3L Antibody [NBP3-00002] - Immunochemical staining of human BNIP3L in human breast carcinoma with rabbit polyclonal antibody at 1:1000 dilution, formalin-fixed paraffin embedded sections.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunohistochemistry-Paraffin-NBP3-00002-img0003.jpg)
![Immunoprecipitation: BNIP3L Antibody [NBP3-00002] - GP-BNIP3L was immunoprecipitated using: Lane A: 0.5 mg K562 Whole Cell Lysate 4 ul anti-GP-BNIP3L rabbit polyclonal antibody and 60 ug of Immunomagnetic beads Protein A/G. Primary antibody: Anti-GP-BNIP3L rabbit polyclonal antibody, at 1:100 dilution. Secondary antibody: Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 36 kDa. Observed band size: 36 kDa](http://images.novusbio.com/fullsize/BNIP3L-Antibody-Immunoprecipitation-NBP3-00002-img0005.jpg)
![Western Blot: BNIP3L Antibody (S01-0F5) [NBP3-19585] - Western blot detection of BNIP3L in Jurkat cell lysates using NBP3-19585 (1:500 diluted). Predicted band size: 24kDa. Observed band size: 38kDa.](http://images.novusbio.com/fullsize/BNIP3L-Antibody-S01-0F5-Western-Blot-NBP3-19585-img0002.jpg "Western Blot: BNIP3L Antibody (S01-0F5) [NBP3-19585] - Western blot detection of BNIP3L in Jurkat cell lysates using NBP3-19585 (1:500 diluted). Predicted band size: 24kDa. Observed band size: 38kDa.")
![Immunohistochemistry-Paraffin: BNIP3L Antibody (S01-0F5) [NBP3-19585] - Immunohistochemistry of BNIP3L in paraffin-embedded Human lung cancer tissue using NBP3-19585 at dilution 1/50](http://images.novusbio.com/fullsize/BNIP3L-Antibody-S01-0F5-Immunohistochemistry-Paraffin-NBP3-19585-img0001.jpg)
![Western Blot: BNIP3L Overexpression Lysate (Adult Normal) [NBL1-08015] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for BNIP3L.](http://images.novusbio.com/fullsize/BNIP3L-Overexpression-Lysate-Adult-Normal-Western-Blot-NBL1-08015-img0002.jpg "Western Blot: BNIP3L Overexpression Lysate (Adult Normal) [NBL1-08015] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for BNIP3L.")